2020
In silico analysis of the immunological landscape of pituitary adenomas
Yeung JT, Vesely MD, Miyagishima DF. In silico analysis of the immunological landscape of pituitary adenomas. Journal Of Neuro-Oncology 2020, 147: 595-598. PMID: 32236778, PMCID: PMC7261241, DOI: 10.1007/s11060-020-03476-x.Peer-Reviewed Original ResearchMeSH KeywordsAdenomaAdultComputational BiologyComputer SimulationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPituitary NeoplasmsConceptsPituitary adenomasImmunological landscapeImmune cellsM2 macrophagesPituitary tumorsAdenoma subtypesSilent pituitary tumorsMemory T cellsImmune cell typesDifferent immunotherapiesHigh CD8Immune infiltratesImmune landscapeSilent tumorsGH tumorsImmunological compositionMacrophage fractionT cellsMast cellsTumor subtypesSolid tumorsSubclinical casesAdenomasTumorsSubtypes
2012
Pegylated interferon-α-2b for children with recurrent craniopharyngioma.
Yeung JT, Pollack IF, Panigrahy A, Jakacki RI. Pegylated interferon-α-2b for children with recurrent craniopharyngioma. Journal Of Neurosurgery Pediatrics 2012, 10: 498-503. PMID: 23061825, DOI: 10.3171/2012.9.peds12225.Peer-Reviewed Original ResearchConceptsMonths of treatmentGross total resectionPatient experienced recurrenceRecurrent craniopharyngiomaExperienced recurrenceSubtotal resectionComplete responseRadiation therapyUse of PIDisease 19 monthsDisease 6 monthsDisease 10 yearsInterferon α-2bStable diseaseDurable responsesIntralesional administrationCystic tumorTumor sizeTumor responseSubcutaneous injectionCystic componentFurther interventionCraniopharyngiomaRecurrenceSustained exposure